本帖最后由 老马 于 2013-3-13 13:43 编辑 + R5 r) b6 J6 g0 @1 r
2 ?# i6 O" N# }. V* [' q健择（吉西他滨）+顺铂+阿瓦斯汀6 [, ]; N# W- o" s# F
Gemzar +Cisplatin + Avastin/ z+ [) H: _+ |. a, Q6 ~$ x0 J! Z; k
http://annonc.oxfordjournals.org/content/21/9/1804.full
: J8 B# e8 }" \( dOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) $ Y% \; i9 @; a1 _0 r
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
' p* c8 h: v" C9 Z) |1 A8 n) ^Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 7 m8 L/ e. L6 V" M2 \
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 796)
$ K& Z# ^4 e# \: ~4 S: F华为网盘附件：
. V' H( N3 f4 L2 Q: }【华为网盘】ava.JPG) B2 s5 H8 Z$ @( F7 v8 p
|
显身卡
